Company intelligence / Profile preview
Surface Logix
Massachusetts, United Statessurfacelogix.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Surface Logix developed several novel small molecule drug candidates using its proprietary Pharmacomer technology. Lead assets included SLx‑2101 (a long‑acting PDE5 inhibitor in Phase II for cardiovascular indications), SLx‑4090 (an oral MTP inhibitor in Phase IIb for dyslipidemia/diabetes), and SLx‑2119 (a selective ROCK2 inhibitor with potential applications across metabolic syndrome, diabetes, cancer, autoimmune diseases). The company demonstrated rapid progression from discovery to clinic but was acquired by Nano Terra around 2011. Some assets were subsequently licensed out or further developed by other companies.
- Therapeutic areas
- Metabolic DisordersCardiovascularEndocrinology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Kadmon Pharmaceuticals
Beyond the preview
Go deeper on Surface Logix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Surface Logix.